LivaNova PLC (NASDAQ:LIVN) Shares Purchased by Gotham Asset Management LLC

Gotham Asset Management LLC boosted its position in LivaNova PLC (NASDAQ:LIVN) by 206.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,219 shares of the company’s stock after acquiring an additional 18,338 shares during the quarter. Gotham Asset Management LLC owned 0.05% of LivaNova worth $1,261,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Deutsche Bank AG raised its holdings in LivaNova by 49.7% in the fourth quarter. Deutsche Bank AG now owns 48,905 shares of the company’s stock valued at $2,265,000 after acquiring an additional 16,227 shares in the last quarter. D. E. Shaw & Co. Inc. increased its stake in LivaNova by 12.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 504,361 shares of the company’s stock valued at $23,357,000 after purchasing an additional 57,723 shares during the last quarter. Corton Capital Inc. purchased a new position in LivaNova in the fourth quarter valued at approximately $214,000. Balyasny Asset Management L.P. increased its stake in LivaNova by 85.4% in the fourth quarter. Balyasny Asset Management L.P. now owns 437,878 shares of the company’s stock valued at $20,278,000 after purchasing an additional 201,682 shares during the last quarter. Finally, Bayesian Capital Management LP purchased a new position in LivaNova in the fourth quarter valued at approximately $218,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of LivaNova in a research note on Tuesday. Barclays dropped their price target on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 8th. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 8th. Finally, Mizuho lowered their target price on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $59.17.

LivaNova Price Performance

LivaNova stock opened at $44.40 on Friday. LivaNova PLC has a one year low of $32.48 and a one year high of $62.95. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The business has a fifty day moving average of $38.39 and a two-hundred day moving average of $44.90. The company has a market cap of $2.42 billion, a P/E ratio of 105.71 and a beta of 0.84.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.